A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis

Publisher: John Wiley & Sons Inc

E-ISSN: 1365-2133|173|3|767-776

ISSN: 0007-0963

Source: BRITISH JOURNAL OF DERMATOLOGY, Vol.173, Iss.3, 2015-09, pp. : 767-776

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content